甲状旁腺切除术对甲状旁腺机能亢进性骨病的远期疗效

为了评价甲状旁腺切除术对原发性甲状旁腺机能亢进（ＰＨＰＴ）所致骨病的远期疗效，回顾分析了１６例术后平均５．１（１．０～１０．５）年患者的临床表现、骨结构和骨密度恢复情况，结果表明手术虽能明显改善患者骨病，但在随访终点有１０／１６例（６２．５％）骨病恢复不全，其中骨病重的Ｙ１组比骨病轻的Ｙ２组恢复不全比例更高（Ｐ＜０．０５），１４／１６例血骨钙素（ＢＧＰ）和尿吡啶并啉（Ｐｙｒ）浓度处于中青年对照组范围内，这意味着其成骨与破骨处于平衡状态。这些结果提示：ＰＨ－ＰＴ患者应尽早诊断治疗，术后应对患者密切随访，重视对骨病恢复不全者的后续治疗     

胰十二指肠切除术后住院时间影响因素分析-回顾性研究

Background. Postoperative hospital stay after pancreaticoduodenectomy (PD) was relatively longer than other gastrointestinal operations, The aim of current study was to investigate the risk factors of postoperative hospital stay after PD. Methods. Patients who were performed PD in Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) between December 2008 and November 2012 were selected for the retrospective study. The clinical and pathological data was collected and analyzed. The primary outcome was postoperative hospital stay. Normal discharge or recovery was defined as postoperative hospital stay no more than 10 days, otherwise it was defined as delayed discharge or recovery (including hospital death). Results. Finally, 152 patients were enrolled in present study. Postoperative hospital stay was 19.7±7.7 (7-57 d). 67 of 152 patients were normal discharge, and 85 of 152 patients were delayed discharge. The overall morbidity of complications was 62.5% (95/152), and the mortality rate was 3.29% (5/152). Multiple factors analysis showed that complication morbidity (adjusted OR=10.40, 95%CI=3.58-30.22), age (adjusted OR=4.09, 95%CI=1.16-14.39), BMI (body mass index) (adjusted OR=4.40, 95%CI=1.19-16.23), surgical procedure (adjusted OR=26.14, 95%CI=4.94-153.19), blood transfusion (adjusted OR=7.68, 95%CI=2.09-28.27) and fluid input (adjusted OR=3.47, 95%CI=1.24-11.57) were significantly associated with delayed discharge. Conclusions. Postoperative complications affects the postoperative hospital discharge. Furthermore, age, BMI, transfused red blood, surgical procedure and input might prolong LOS (length of hospital stay). Studies with more patients were needed in future.     

甲磺酰胺苯乙胺类化合物抗心律失常活性的定量构效关系研究(Ⅰ)

以ＰＯＬＹＧＥＮ软件中的ＣＨＡＲＭｍ程序和集团坐标轮换法，对合成的１２个甲磺酰胺苯乙胺类化合物的结构进行计算机分子模拟。根据所得化合物的能量最低构象，计算了其ＶＤＷ体积、偶极矩、总键能、总键角能、总非正则能以及氮原子电荷等值，并对这些化合物进行ＣＮＤＯ／２法量化计算，这些计算结果作为结构参数分别与１２个化合物抗心律失常活性进行相关分析，以逐步回归法建立了两个相关性较好的方程：ｌｇｌ／ＭＥＣ＝６．９９９１－０．３８４２Ｘ２＋３．６７９６Ｘ５［ｎ＝１２，ｒ＝０．８５５９７５，ｓ＝０．１８９６７２，Ｆ＝１２．３３４６４＞Ｆ１－０．０５（３，９）＝３．８６］；ｌｇｌ／ＭＥＣ＝１４．７０３８－２１３．２６９２Ｘ４－１０．４８２９Ｘ５［ｎ＝１２，ｒ＝０．９３１９１９，ｓ＝０．１３３０４７，Ｆ＝２９．７１３５４＞Ｆ１－０．０１（３，９）＝６．９９］。结果提示，这类化合物的抗心律失常活性与分子中的原子轨道杂化程度和氮原子对分子ＨＯＭＯ和ＬＵ－ＭＯ的贡献有关，可以看出，氮上的取代不同会引起抗心律失常活性的不同     

基于网络药理学探讨独活-羌活-细辛治疗膝骨关节炎的作用机制*

目的 基于网络药理学的方法分析和预测独活-羌活-细辛治疗膝骨关节炎可能的作用机制。方法 利用TCMSP数据库获取独活、羌活、细辛的活性成分及靶点,与CTD、NCBI等数据库获取的膝骨关节炎疾病基因靶点映射,构建药物-活性成分-疾病靶点网络。进行MCODE聚类分析,通过Omicshare云平台和DAVID数据库GO、KEGG通路富集分析。结果 从3味药中共筛选出了36个活性成分及205个靶点,主要有山柰酚、 β-谷甾醇、芝麻脂素、异紫花前胡苷等关键成分,AKT1、ESR1、JUN、CASP3等为关键靶点,核心基因有NOS3、ESR1、COX1、NR1I2,关键的生物进程和通路有类固醇激素反应性、活性氧代谢过程、AGE-RAGE通路和TNF通路。结论 独活-羌活-细辛可能通过多成分、多靶点网络来治疗膝骨关节炎。     

欧洲刺柏（Juniper）

活性成分与药理作用欧洲刺柏药用部位是其浆果，具有促水排泄、防腐、抗胃肠胀气和抗风湿作用，还可改善胃功能。用作促水排泄药可增加尿量（水丢失），但不增加钠排泄。成分萜品烯-4-醇可增加肾小球滤过率，但刺激肾。欧洲刺柏浆果对单纯疱疹病毒体外显示抗病毒活性，并具抗真菌活性。动物实验显示，欧洲刺柏浆果提取物具有堕胎、抗生育、抗炎、抗胚胎植入、降血压、升血压和降血糖作用。欧洲刺柏浆果油具有兴奋子宫的活性，以及利尿、胃肠道抗菌和刺激作用，该油对平滑肌有阻止解痉作用。     

矮身材儿童血铅镉锌钙铁铜镁水平分析

目的探讨血铅、镉、锌、钙、铁、铜、镁水平对儿童生长发育的影响。方法通过采用钨舟原子吸收光谱仪测定我院儿保门诊53例矮身材儿童（矮身材组）及53例正常儿童（对照组）末梢静脉血中铅、镉、锌、钙、铁、铜、镁水平,并对其与儿童生长发育关系进行分析。结果矮身材儿童血铅明显高于正常对照组,锌、钙、铁明显低于正常对照组（P〈0．05）。而血镉、铜、镁与对照组则无明显差异。矮身材组血铅男童明显高于女童（P〈0．05）。结论矮身材儿童的生长发育迟缓可能与高血铅,低血锌、钙、铁密切相关。儿童铅中毒防治和合理的膳食结构是降低儿童矮身材发生率的重要措施。     

原子吸收火焰法测定合力康粉剂中钾、钠、钙、镁、锌、铁的含量

目的：采用原子吸收火焰法测定合力康粉剂中钾、钠、钙、镁、锌、铁的含量。方法：用盐酸-硝酸-水(9：1．5：25)混酸湿法水浴加热消化处理样品，硝酸锶作镁离子释放剂，乙炔-空气火焰原子吸收法。结果：钾、钠、钙镁、锌、铁加样回收率与RSD(n=5)分剐为98．3％、0．8％；100．8％、3．2％；101．8％、1．3％；102．5％、2．1％；101．2％、2．8％；97．4％、2．4％。特征浓度分别为(产生0．0044吸收所需要的浓度，μg/m1)0．02、0．01、0．07、0．003、0．0l、0．06。结论：该方法简便、快速、结果准确，适用于合力康粉剂粉剂中钾、钠、钙、镁、锌、铁的含量测定。     

自发性蛛网膜下腔出血后不同危险级别患者脑血管痉挛的MSCTA评价

目的：探讨自发性蛛网膜下腔出血（SAH）后不同危险级别患者的脑血管痉挛（CVS）程度是否存在差异。方法：对32例SAH患者进行低、高危险级别分组后,与多层螺旋CT血管成像（MSCTA）评价的CVS程度进行比较,所有病例均经数字减影血管造影（DSA）证实。结果：本组32例患者中,低危险级别25例,高危险级别7例,发生CVS患者12例（占37.5%）。25例低危级别患者中,18例（占72%）MSCTA表现正常,7例（占28.0%）出现轻度CVS,多无临床体征;7例高危级别患者中,2例（占28.6%）MSCTA表现正常,5例（占71.4%）出现中重度CVS,临床表现为迟发性缺血性神经功能缺失。低、高危险级别患者与MSCTA检出的CVS程度比较,Z=-2.936,P〈0.05。结论：MSCTA可准确无创地评价SAH后CVS程度,指导临床分组治疗。     

Pleura, pleural cavity, mediastinum, diaphragm

Thoracic primitive neuroectodermal tumor, Long-term effects of thymectomy on the T cellular immunity of myasthenia gravis patients .     

Liver, biliary tract, pancreas, spleen

207577 Pathologic and molecular biologic characteris- tics of hilar cholangiocarcinomas/Li Chenggang(李成 刚,Inst Hepatobil Surg, Gener Hosp PLA, Beijing 100853)…∥Chin J Exp Surg.-2007 ,24(6) .-690 ~ 691 Objective Toinvestigate the pathologic and molec- ular biologic characteristics of hilar cholangiocarcinomas. Methods Sixty-eight patients with hilar cholangio- carcinomas were reviewed,and the pathologic types and incidence of perineural invasionandlymph node metastasis were summariz…     

Liver, biliary tract, pancreas, spleen

Experimental study on bone marrow mononuclear cells on vWF and VEGF expression in ischemic bile duct tissue; Study on molecular mechanism of vasculogenic mimicry in hepatocdlular carcinoma; Study on side population ceils in human hepatocellular carcinoma cell line 97H; Budd-Chiari syndrome associated with hepatocellular carcinoma： a report of 10 cases; Correlation of aPKC-t and E-cadherin expression with invasion and prognosis of extrahepatic cholangioeareinoma……     

Liver,biliary tract,pancreas,spleen

<正>209054 Liver protection of prostaglandin E1in patients after hepatectomy/Hua Yunpeng(华赟鹏,Dept Hepatobil Surg,1st Affil Hosp,Sun Yat-sen Univ,Guang-zhou 510080)…∥Chin J Gen Surg. -2009,24(10). -817～819 Objective To investigate the effect and mechansim of prostaglandin E1(PGE1) to protect liver functions after hepatectomy.     

Liver,biliary tract,pancreas,spleen

<正>209178 Long-term prevention of virus recurrence among recipients with HBV active replication following liver transplantation/Dai Jun(Liver Transplant Center,West Chin Hosp,Sichuan Univ,Chengdu 610041)…∥Chin J Hepatobil Surg.-2009,15(2).-106~109Objective To investigate the long-term prophylactic outcome in recipierts with HBV active replication under LAM or/and HBIG prophylaxis after liver transplantation.Methods The liver biopsy specimens and serum samples were collected during the follow-up.ELISA and chemiluminesent microparticle immunoassay,HBV-DNA fluorescent quantification,immunohistochemisty and HBV-DNA in situ hybridization were performed for analysis.The alteratio of HBV markers in serial biopsy and sera of 55 recipients were investigated retrospectively.Results The mean time of follow-up was 69.14 months.Twelve cases had hepatitis B virus reinfection after transplantation.The accumulated ratio of hepatitis B virus reinfection was 4.8%(2/42)in LAM+HBIG group and 76.9%(10/13) in LAM monoprophylaxis group(P=0.000).The 1-,2-,3-and 4-yr,survival rates in combined prophylaxis group were 100%,97.1%,92.7% and 92.7%,respectively.The 1-,2-,3-and 4-yr survival rates in LAM mono prophylaxis group were 76.9%,69.2%,53.8% and 46.2%,respectively(P=0.000).The rates of hepatitis B virus reinfection in combination prophylaxis group(1-,2-,3-and 4-yr recurrence rates of 2.4%,2.4%,2.4%,and 8.5%,respectively) was markedly lower than those in mono prophylaxis group(1-,2-,3-and 4-yr recurrence rates of 16.1%,41.3%,66.4% and 66.4%,respectively)(P=0.000).Conclusion Currently HBIG combined with LAM is an optimal prophylatic protocol to reduce the hepatitis B virus reifection rate.However,poor compliance of recipients to a prescribed course of prophylaxis as well as viral staus itself is still the main cause of hepatitis B virus reinfection after liver transplantation in China.Compliance education and adjusting the prophylatic protocols according to the viral alteration after liver transplantation may help to fur